C. Loirat and V. Frémeaux-bacchi, Atypical hemolytic uremic syndrome, Orphanet J Rare Dis, vol.6, p.60, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01064383

V. Fremeaux-bacchi, F. Fakhouri, and A. Garnier, Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, issue.4, pp.554-562, 2013.

D. Kavanagh and T. Goodship, Genetics and complement in atypical HUS, Pediatr Nephrol, vol.25, issue.12, pp.2431-2442, 2010.

P. Sánchez-corral and M. Melgosa, Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome, Br J Haematol, vol.150, issue.5, pp.529-542, 2010.

L. T. Roumenina, C. Loirat, M. A. Dragon-durey, L. Halbwachs-mecarelli, C. Sautes-fridman et al., Alternative complement pathway assessment in patients with atypical HUS, J Immunol Methods, vol.365, issue.1-2, pp.8-26, 2011.

P. Warwicker, T. H. Goodship, and R. L. Donne, Genetic studies into inherited and sporadic hemolytic uremic syndrome, Kidney Int, vol.53, issue.4, pp.836-844, 1998.

A. Richards, E. J. Kemp, and M. K. Liszewski, Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome, Proc Natl Acad Sci USA, vol.100, issue.22, pp.12966-12971, 2003.

V. Fremeaux-bacchi, M. A. Dragon-durey, and J. Blouin, Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome, J Med Genet, vol.41, issue.6, p.84, 2004.

M. Delvaeye, M. Noris, D. Vriese, and A. , Thrombomodulin mutations in atypical hemolyticuremic syndrome, N Engl J Med, vol.361, issue.4, pp.345-357, 2009.

V. Frémeaux-bacchi, E. C. Miller, and M. K. Liszewski, Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome, Blood, vol.112, issue.13, pp.4948-4952, 2008.

J. E. Goicoechea-de, C. L. Harris, and J. Esparzagordillo, Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome, Proc Natl Acad Sci USA, vol.104, issue.1, pp.240-245, 2007.

M. A. Dragon-durey, C. Loirat, and S. Cloarec, AntiFactor H autoantibodies associated with atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.16, issue.2, pp.555-563, 2005.

F. Fakhouri, L. Roumenina, and F. Provot, Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, issue.5, pp.859-867, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00512540

F. Fakhouri, V. Frémeaux-bacchi, and C. Loirat, Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy, Eur J Intern Med, vol.24, issue.6, pp.492-495, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02164555

J. Zuber, F. Fakhouri, L. T. Roumenina, and C. Loirat, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, issue.11, pp.643-657, 2012.

M. Lemaire, V. Frémeaux-bacchi, and F. Schaefer, Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, vol.45, issue.5, pp.531-536, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01064383

R. Westland, M. Bodria, and A. Carrea, Phenotypic expansion of DGKE-associated diseases, J Am Soc Nephrol, vol.25, issue.7, pp.1408-1414, 2014.

Y. V. Shulga, M. K. Topham, and R. M. Epand, Regulation and functions of diacylglycerol kinases, Chem Rev, vol.111, issue.10, pp.6186-6208, 2011.

Y. V. Shulga, M. K. Topham, and R. M. Epand, Substrate specificity of diacylglycerol kinase-epsilon and the phosphatidylinositol cycle, FEBS Lett, vol.585, issue.24, pp.4025-4028, 2011.

R. M. Epand and M. K. Topham, Measurement of mammalian diacylglycerol kinase activity in vitro and in cells, Methods Enzymol, vol.434, pp.293-304, 2007.

F. Ozaltin, B. Li, and A. Rauhauser, DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN, J Am Soc Nephrol, vol.24, issue.3, pp.377-384, 2013.

T. R. Pettitt, A. Martin, T. Horton, C. Liossis, J. M. Lord et al., Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. Phospholipase D-derived diacylglycerol does not activate protein kinase C in porcine aortic endothelial cells, J Biol Chem, vol.272, issue.28, pp.17354-17359, 1997.

Z. Naor, O. Benard, and R. Seger, Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor, Trends Endocrinol Metab, vol.11, issue.3, pp.91-99, 2000.

S. E. Quaggin and . Dgke, Nat Genet, vol.45, issue.5, pp.475-476, 2013.

H. M. Verheul, A. S. Jorna, K. Hoekman, H. J. Broxterman, M. F. Gebbink et al., Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets, Blood, vol.96, issue.13, pp.4216-4221, 2000.

J. S. Arthur, MSK activation and physiological roles, Front Biosci, vol.13, pp.5866-5879, 2008.

J. M. Ku?do, K. I. Ogawara, and N. Werner, Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases, Curr Vasc Pharmacol, vol.3, issue.1, pp.11-39, 2005.

M. Frimat, F. Tabarin, and J. D. Dimitrov, Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome, Blood, vol.122, issue.2, pp.282-292, 2013.

L. T. Roumenina, M. Frimat, and E. C. Miller, A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function, Blood, vol.119, issue.18, pp.4182-4191, 2012.

G. Mavria, Y. Vercoulen, and M. Yeo, ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis, Cancer Cell, vol.9, issue.1, pp.33-44, 2006.

T. Matsumoto, I. Turesson, M. Book, P. Gerwins, C. et al., p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis, J Cell Biol, vol.156, issue.1, pp.149-160, 2002.

U. Förstermann and T. Münzel, Endothelial nitric oxide synthase in vascular disease: from marvel to menace, Circulation, vol.113, issue.13, pp.1708-1714, 2006.

E. M. Paleolog, D. C. Crossman, J. H. Mcvey, and J. D. Pearson, Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells, Blood, vol.75, issue.3, pp.688-695, 1990.

U. M. Vischer and C. B. Wollheim, Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca21 and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis, Blood, vol.91, issue.1, pp.118-127, 1998.

O. Lorenzi, M. Frieden, P. Villemin, M. Fournier, M. Foti et al., Protein kinase C-delta mediates von Willebrand factor secretion from endothelial cells in response to vascular endothelial growth factor (VEGF) but not histamine, J Thromb Haemost, vol.6, issue.11, pp.1962-1969, 2008.

M. A. Carew, E. M. Paleolog, and J. D. Pearson, The roles of protein kinase C and intracellular Ca21 in the secretion of von Willebrand factor from human vascular endothelial cells, Biochem J, vol.286, issue.2, pp.631-635, 1992.

D. Sánchez-chinchilla, S. Pinto, and B. Hoppe, Complement mutations in diacylglycerol kinasee-associated atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.9, issue.9, pp.1611-1619, 2014.

B. Renner, J. Klawitter, and R. Goldberg, Cyclosporine induces endothelial cell release of complement-activating microparticles, J Am Soc Nephrol, vol.24, issue.11, pp.1849-1862, 2013.

M. Furlan, R. Robles, and M. Galbusera, von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome, N Engl J Med, vol.339, issue.22, pp.1578-1584, 1998.

V. Eremina, J. A. Jefferson, and J. Kowalewska, VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, vol.358, issue.11, pp.1129-1136, 2008.

M. A. Karmali, M. Petric, C. Lim, P. C. Fleming, G. S. Arbus et al., The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli, J Infect Dis, vol.151, issue.5, pp.775-782, 1985.